Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarin’s Momentum Grows With Twin Blockbuster Plans

Dwarfism Drug Data Look Promising

Executive Summary

The frontrunner in hemophilia A gene therapy has been hit by data doubts, but this and achondroplasia drug could deliver in 2020.

You may also be interested in...



BioMarin CEO Suggests Hemophilia Gene Therapy Pricing In $2m-$3m Range

During BioMarin’s earnings call Feb. 21, CEO Bienaime indicated the company may be looking to price its valoctocogene roxaparvovec gene therapy at $2m-$3m, as it would represent a savings over the annual cost of infused clotting factor therapy.

J&J’s Darzalex Scores Again In Frontline Myeloma

Janssen’s hemato-oncology success rolls on with impressive new overall survival data

As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside

While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141195

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel